COLITIS also see BOWEL DISORDERS

 

Ulcerative Colitis and Marijuana                    (letter – 1990)

http://www.druglibrary.org/schaffer/hemp/medical/colitis1.htm

 

Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium.                                                           (full – 2006)  http://ajpgi.physiology.org/content/291/2/G364.long

 

Ulcerative colitis in AKR mice is attenuated by intraperitoneally administered anandamide.         (full – 2008)  http://www.jpp.krakow.pl/journal/archive/12_08/pdf/673_12_08_article.pdf

 

Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors.                                                                       (abst – 2008)  http://www.ncbi.nlm.nih.gov/pubmed/18493729

 

Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. (full – 2009)                                        http://onlinelibrary.wiley.com/doi/10.1002/ibd.20960/full

 

Ulcerative Colitis Induces Changes on the Expression of the Endocannabinoid System in the Human Colonic Tissue                                                               (full – 2009)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731878/?tool=pmcentrez

 

Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis.                                                           (abst – 2009)  http://www.unboundmedicine.com/medline/ebm/record/19690824/abstract/Cannabidiol_a_safe_and_non_p sychotropic_ingredient_of_the_marijuana_plant_Cannabis_sativa_is_protective_in_a_murine_model_of_c olitis_

 

Cannabis for Ulcerative Colitis and Crohn’s Disease treatment                      (news – 2009)  http://www.news-medical.net/news/20091217/Cannabis-for-Ulcerative-Colitis-and-Crohns-Disease-  treatment.aspx

 

Medical Marijuana and Colitis                       (news – 2009)

https://www.marijuanadoctors.com/content/ailments/view/132?ailment=colitis

 

The Cannabinoid 1 Receptor (CNR1) 1359 G/A Polymorphism Modulates Susceptibility to Ulcerative Colitis and the Phenotype in Crohn’s Disease                                                            (full – 2010)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829088/?tool=pmcentrez

 

Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis.                                                                          (full – 2010)  http://www.jpp.krakow.pl/journal/archive/02_10/pdf/89_02_10_article.pdf

 

 

 

 

 

 

 

 

 

The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis.                                                          (full – 2010)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931570/?tool=pubmed

 

The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment.                                                   (abst – 2010)       http://www.ncbi.nlm.nih.gov/pubmed/21080464

 

Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis (full – 2011)                                  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232190/?tool=pubmed

 

Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation.       (full – 2011)                                        http://www.fasebj.org/content/25/8/2711.long

 

β-Caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPARγ pathway.                                                   (abst – 2011)  http://www.ncbi.nlm.nih.gov/pubmed/21356367

 

Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases.  (abst – 2011)                                            http://www.ncbi.nlm.nih.gov/pubmed/21876860

 

Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis.                                                                      (abst – 2011)  http://www.ncbi.nlm.nih.gov/pubmed/22119709

 

The JNK inhibitor XG-102 protects against TNBS-induced colitis.  (full – 2012)

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302790/

 

Topical and Systemic Cannabidiol Improves Trinitrobenzene Sulfonic Acid Colitis in Mice.         (full – 2012)                      http://content.karger.com/produktedb/produkte.asp?DOI=000336871&typ=pdf

 

The atypical cannabinoid O-1602 shows antitumorigenic effects in colon cancer cells and reduces tumor growth in a colitis-associated colon cancer model                                                              (full – 2012)  http://www.biomedcentral.com/content/pdf/2050-6511-13-S1-A23.pdf

 

The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity.                                                     (abst – 2012)      http://www.ncbi.nlm.nih.gov/pubmed/22917662

 

N-                           02, an atypical cannabinoid, inhibits tumor growth in colitis-associated colon cancer through multiple mechanisms.                  (abst          – 2012)    http://www.ncbi.nlm.nih.gov/pubmed/22965195

 

4-Oxo-1,4-dihydropyridines as Selective CB2 Cannabinoid Receptor Ligands Part 2: Discovery of New Agonists Endowed with Protective Effect Against Experimental Colitis.      (abst – 2012)                         http://www.ncbi.nlm.nih.gov/pubmed/23017078

 

The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity.                                                     (abst – 2012)  http://www.ncbi.nlm.nih.gov/pubmed/22917662?dopt=Abstract

 

 

 

 

 

 

 

 

 

The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.                                                                       (abst – 2013)  http://www.ncbi.nlm.nih.gov/pubmed/23373571

 

Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis.                                                                        (abst – 2013)  http://www.ncbi.nlm.nih.gov/pubmed/23381627

 

Prostaglandin ethanolamides attenuate damage in a human explant colitis model (abst – 2013)                                            http://www.ncbi.nlm.nih.gov/pubmed/23380599

 

Share a link for